NewsNORDTuesday, February 24, 2026 · February 24, 2026
NORD CEO Statement on FDA Draft Guidance for the Plausible Mechanism Framework for Individualized Genetic Therapies
WHY IT MATTERS
NORD advocacy and policy updates affecting the rare disease community.
NORD is encouraged by efforts to strengthen and clarify regulatory tools that advance rare disease treatments. For conditions with extremely small patient populations, where traditional clinical trials are difficult to … Continue reading "NORD CEO Statement on FDA Draft Guidance for the Plausi
Related news
NORD · Today
Access to Answers — Bridging the Gap to Genetic Expertise
Congress is currently considering the Access to Genetic Counselor Services Act (H.R. 6280/S. 3607), a bipartisan piece o…
NORD · Yesterday
Recap: NORD Living Rare, Living Stronger in Arizona
Since 2019, the National Organization for Rare Disorders (NORD®) Living Rare, Living Stronger® Patient & Family Foru…
NORD · 3 days ago
Vermont Governor Signs Rare Disease Advisory Council into Law
H.46 makes Vermont the 34th state in the nation – including all states in New England – to give rare disease patients a …
NORD · 4 days ago
Guest Blog: Uniting for Behçet’s Disease Awareness on May 20
By Ashley Pelletier, Executive Director of the American Behcet’s Disease Association (ABDA) On May 20, Behçet’s Disease …